关于持股 5%以上股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律 责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，上海复旦张江生物医药股份有限公司（以下简称"公 司"或"复旦张江"）股东杨宗孟先生持有公司股份 74,375,494 股，占公司总股本 的 7.18%；王海波先生持有公司股份 56,099,327 股，占公司总股本的 5.41%。上 述股东所持有的公司股份来源为公司首次公开发行前持有的股份数量，该部分股 份已于 2023 年 6 月 19 日起全部解除限售并上市流通。 证券代码：688505 证券简称：复旦张江 公告编号：临 2025-024 上海复旦张江生物医药股份有限公司 集中竞价减持计划的实施结果情况 1、2025 年 6 月 23 日，公司于上海证券交易所网站（www.sse.com.cn）披露 了《关于持股 5%以上股东减持股份计划公告》（公告编号：临 2025-018）。因自 身资金需求，杨宗孟先生计划通过集中竞价交易的方式减持公司股份不超过 10,365 ...

Summary of Key Points Core Viewpoint - Fudan Zhangjiang announced that shareholders Yang Zongmeng and Wang Haibo will reduce their holdings in the company through centralized bidding transactions, impacting the total shareholding structure of the company [1] Shareholder Reduction Details - Yang Zongmeng will reduce his holdings by 10.3657 million shares, which accounts for 1.00% of the company's total share capital, between July 14 and July 16, 2025 [1] - Wang Haibo will reduce his holdings by 4.2707 million shares, representing 0.41% of the company's total share capital, between July 14 and July 15, 2025, and has decided to terminate his reduction plan early [1] Post-Reduction Shareholding - After the reduction, Yang Zongmeng will hold 64.0098 million shares, which is 6.18% of the total shares [1] - After the reduction, Wang Haibo will hold 51.8286 million shares, which is 5.00% of the total shares [1]

Company Overview - Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. was established in November 1996 in the Zhangjiang Hi-Tech Park, Shanghai, with notable shareholders including Shanghai Pharmaceutical Group [2] - The company focuses on innovative research, development, production, and sales in the biopharmaceutical sector, aiming to become a leading innovation enterprise centered on intellectual property [2] - Fudan Zhangjiang has developed competitive advantages in areas such as gene technology drugs, photodynamic therapy drugs, nanotechnology drugs, and oral solid dosage forms, with new products expected to be launched in the future [2] - The company has been recognized as a "High-tech Enterprise" in Shanghai since 1998 and has been involved in several national key technology projects [2] - Fudan Zhangjiang is listed on both the Hong Kong Stock Exchange and the Shanghai Stock Exchange, making it one of the few companies with A+H share listings [2] Financial Performance - As of March 31, 2025, Fudan Zhangjiang reported total revenue of 180 million yuan, a year-on-year increase of 21.85% [1] - The net profit attributable to shareholders was 2.6651 million yuan, reflecting a year-on-year growth of 13.53% [1] - The company's gross margin stood at 91.08%, with a debt-to-asset ratio of 8.82% [1] Stock Performance - As of July 17, the stock price of Fudan Zhangjiang was 4.4 HKD per share, marking a 14.29% increase with a trading volume of 373 million shares and a turnover of 1.744 billion HKD [1] - Over the past month, the stock has gained 14.31%, and year-to-date, it has increased by 57.99%, outperforming the Hang Seng Index, which rose by 22.22% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.45 times, with a median of 6.93 times [1] - Fudan Zhangjiang's P/E ratio is significantly higher at 92.37 times, ranking 73rd in the industry [1] - Comparatively, other companies in the sector have lower P/E ratios, such as Qianjing Pharmaceutical at 0.9 times and King’s Ray Biotechnology at 1.46 times [1]

Group 1: Stock Performance - Zhejiang Zhenyuan and Asia-Pacific Pharmaceutical both achieved a 2-day limit-up with increases of 10.01% and 9.98% respectively, driven by innovation in pharmaceuticals [2] - Chengdu XianDao saw a first board listing with a significant rise of 20.02%, attributed to innovative drug developments [2] - TaiJing Technology and YanHua Intelligent both recorded first board listings with increases of 9.97% and 9.94%, linked to Huawei's influence in robotics [5] Group 2: AI and Robotics - Nvidia's CEO suggested that Huawei's AI chips could potentially replace Nvidia's offerings, indicating a competitive shift in the AI chip market [4] - The domestic robotics industry is gaining traction with significant orders being awarded, highlighting its importance in national competition [7] Group 3: Market Trends - The light communication sector is expected to see sustained growth due to high demand in both domestic and international markets, with performance likely to continue improving [13] - The low-altitude economy is gaining attention, with a notable $1 billion procurement agreement signed for eVTOL aircraft, indicating growth potential in this sector [17] Group 4: Consumer and Retail - The Chinese government is implementing measures to boost consumer spending, which is expected to positively impact the retail sector [21] - Companies like Guoguang Chain and Hanshang Group have seen first board listings with increases of 9.98% and 9.97%, reflecting the positive sentiment in the retail market [23] Group 5: Solar and Food & Beverage - The price of polysilicon has increased by 12.4% week-on-week, indicating a rising trend in the solar industry [24] - The food and beverage sector is also benefiting from government initiatives aimed at enhancing consumer demand, with companies like Huangshi Group seeing a 10.10% increase [26]

Market Overview - The A-share market opened slightly lower on July 17 but then experienced a rebound, with all three major indices showing positive performance, particularly the ChiNext index which rose nearly 1% [2] - The total market capitalization reached 14.20 trillion CNY, with a trading volume of 7698.06 million hands and a turnover rate of 1.46% [3] Pharmaceutical Sector - The pharmaceutical sector saw a significant surge, with multiple stocks hitting the daily limit up, including Weikang Pharmaceutical and Chengdu Xian Dao, both reaching a 20% increase [4][5] - Notable stocks in the pharmaceutical sector included: - Chengdu Xian Dao: 21.46 CNY, up 20.02% - Weikang Pharmaceutical: 20.71 CNY, up 19.99% - Other stocks like Lifespring Pharmaceutical and Zhejiang Zhenyuan also saw increases of around 10% [5][6] - The Hong Kong pharmaceutical and biotechnology sector also experienced notable gains, with companies like Fudan Zhangjiang and Kanyin Biotech showing significant price increases [6] Robotics Sector - The humanoid robot concept stocks remained active, with Nanjing Julong hitting the daily limit up of 20%, and other companies like Dongshan Precision and Taijing Technology also seeing substantial gains [7][8] - On July 17, the stock of Aowei New Materials achieved a 20% limit up, marking its seventh consecutive trading day of gains, with a closing price of 27.89 CNY [10][11] Policy Impact - The National Healthcare Security Administration recently announced the initiation of the 11th batch of centralized drug procurement, which will include 55 drug varieties, focusing on mature "old drugs" while excluding innovative drugs from the procurement list [6]

Group 1 - The core viewpoint of the news is that the Hong Kong stock market, particularly the healthcare sector, is experiencing a strong rally driven by the revaluation of innovative drug companies, with significant increases in stock prices and ETF performance [1][2]. - The CSI Hong Kong Innovative Drug Index rose by 4.23%, with notable gains from companies such as Fudan Zhangjiang (over 18% increase), Lepu Biopharma-B (over 10% increase), and Kangfang Biotech (over 9% increase) [1]. - The Hong Kong Innovative Drug 50 ETF (513780) saw a 3.57% increase, with a trading volume exceeding 200 million yuan within the first half hour of trading [1]. Group 2 - According to Jiao Yin International, the current innovative drug market in Hong Kong is driven by value re-evaluation, with attractive valuations compared to U.S. counterparts, as leading innovative drug companies have a forward 12-month price-to-sales ratio around 3 times, lower than the U.S. average of 4 times [2]. - Donghai Securities noted that the domestic innovative drug sector has seen increased activity this year, with high-value business development transactions and rising R&D investments, indicating a potential systematic recovery in the CXO and upstream life sciences sectors [2]. - Investment opportunities are suggested in various sub-sectors including CXO, innovative drugs, medical devices, traditional Chinese medicine, chain pharmacies, and medical services [2].

Group 1 - The National Healthcare Security Administration has initiated the 11th batch of centralized drug procurement, with 55 drug varieties included in the reporting range [1] - The procurement principles emphasize maintaining clinical stability, ensuring quality, preventing collusion, and avoiding excessive competition, with a focus on non-new drugs [1] - The current valuation of leading innovative drug companies in Hong Kong is attractive, with a forward 12-month price-to-sales ratio around 3 times, lower than the US average of 4 times [1] Group 2 - Domestic interest in innovative drugs has surged this year, with significant BD transactions and increased R&D investment from innovative drug companies [2] - The Hong Kong pharmaceutical and biotechnology sector has shown strength, with notable stock price increases for companies like 开拓药业 (over 20%) and 复旦张江 (over 20%) [2] - The CXO and upstream life sciences sectors are expected to stabilize and improve, presenting systemic recovery opportunities [2]

Group 1: Fudan Zhangjiang - Fudan Zhangjiang is advancing its DC platform and photodynamic technology platform, with multiple antibody-drug conjugates in various clinical stages for treating cancers such as triple-negative breast cancer, bladder cancer, and gastric cancer [1] - The company is conducting Phase III clinical studies for anti-Trop2 antibody-drug conjugates and has completed the first subject enrollment for a clinical trial involving aminolevulinic acid granules for non-muscle invasive bladder cancer [1] - Fudan Zhangjiang plans to increase R&D investment to further promote the progress of its research projects [1] Group 2: Xiangyu Medical - Xiangyu Medical's research indicates a clear and significant demand for non-invasive brain-machine interfaces in rehabilitation, sleep monitoring, and attention enhancement [2] - The company has developed two EEG collection devices that have received Class II medical device registration and expects to obtain multiple registrations for brain-machine interface products in the second half of the year [2] - Xiangyu Medical's sales strategy involves starting with top-tier hospitals and gradually expanding to lower-tier hospitals and community health centers, with plans to enter the home market [2]

Core Points - The report indicates that Wang Haibo has reduced his shareholding in Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. from 5.41% to 5.00%, marking the first time his holding has fallen below 5% [1][4] - The reduction was executed through centralized bidding, with a total of 4,270,722 shares sold, representing 0.41% of the company's total share capital [4][8] - The purpose of this share reduction is attributed to Wang Haibo's personal funding needs, as stated in the previously announced reduction plan [3][4] Summary by Sections Section 1: Definition - The report defines key terms, including the information disclosure obligor (Wang Haibo) and the company (Shanghai Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd.) [2] Section 2: Information Disclosure Obligor - Wang Haibo is identified as the information disclosure obligor, with no other significant shareholdings in other listed companies [3] Section 3: Purpose of Equity Change - The equity change is primarily driven by Wang Haibo's funding needs, as outlined in a prior announcement regarding the reduction plan [3][4] Section 4: Method of Equity Change - Prior to the equity change, Wang Haibo held 56,099,327 shares (5.41% of total shares). After the reduction, he holds 51,828,605 shares (5.00%) [4][6] - The shares were sold between July 14 and July 15, 2025, through centralized bidding [4][8] Section 5: Trading History - There were no other transactions involving the company's shares by Wang Haibo in the six months preceding the report [5][8] Section 6: Other Significant Matters - The report confirms that all relevant information regarding the equity change has been disclosed accurately and completely [6][8]

Core Viewpoint - The announcement details a change in shareholding by major shareholder Wang Haibo, who has reduced his stake in Fudan Zhangjiang Bio-Pharmaceutical Co., Ltd. to 5% through a planned share reduction, which does not trigger a mandatory takeover bid [1][2]. Summary by Sections 1. Basic Information of the Shareholder - Wang Haibo is a Chinese national and holds permanent residency in Hungary [1]. 2. Details of the Shareholding Change - Wang Haibo reduced his shareholding from 56,099,327 shares (5.41%) to 51,828,605 shares (5.00%) by selling 4,270,722 shares through centralized bidding from July 14 to July 15, 2025 [1]. - The reduction in shareholding does not affect the control of the company as there is no controlling shareholder or actual controller [1][2]. 3. Shareholding Status Before and After the Change - Before the change: Wang Haibo held 56,099,327 shares (5.41% of total share capital) - After the change: Wang Haibo holds 51,828,605 shares (5.00% of total share capital) [1]. 4. Compliance with Regulations - The shareholding change complies with relevant regulations and does not violate any laws or guidelines regarding shareholder reductions [3].